Dariush Etemadmoghadam

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Figures 1 - 15 from Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with <i>BRCA1</i> and <i>BRCA2</i> MutationsPreprint

  2023-03-31

• Data from Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with <i>BRCA1</i> and <i>BRCA2</i> MutationsPreprint

  2023-03-31

• Supplementary Table 16 from Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with <i>BRCA1</i> and <i>BRCA2</i> Mutations

  2023-03-31

• Supplementary Methods and Tables 1 - 15, 19 from Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with <i>BRCA1</i> and <i>BRCA2</i> MutationsPreprint

  2023-03-31

• Supplementary Table 18 from Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with <i>BRCA1</i> and <i>BRCA2</i> Mutations

  2023-03-31

• Supplementary Table 17 from Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with <i>BRCA1</i> and <i>BRCA2</i> Mutations

  2023-03-31

• Supplementary Data from Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian CarcinomasPreprint

  2023-03-31

• Supplementary Table 17 from Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with <i>BRCA1</i> and <i>BRCA2</i> Mutations

  2023-03-31

• Supplementary Table 16 from Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with <i>BRCA1</i> and <i>BRCA2</i> Mutations

  2023-03-31

• Supplementary Methods and Tables 1 - 15, 19 from Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with <i>BRCA1</i> and <i>BRCA2</i> MutationsPreprint

  2023-03-31

• Supplementary Table 18 from Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with <i>BRCA1</i> and <i>BRCA2</i> Mutations

  2023-03-31

• Supplementary Methods from Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in <i>CCNE1</i>-Amplified Ovarian CancerPreprint

  2023-03-31

• Supplementary Data from Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in <i>CCNE1</i>-Amplified Ovarian CancerPreprint

  2023-03-31

• Supplementary Figures S1-S9 from Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in <i>CCNE1</i>-Amplified Ovarian CancerPreprint

  2023-03-31

• Supplementary Tables S1-5 from Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in <i>CCNE1</i>-Amplified Ovarian Cancer

  2023-03-31

• Supplementary Data from Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian CarcinomasPreprint

  2023-03-31

• Supplementary Methods from Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in <i>CCNE1</i>-Amplified Ovarian CancerPreprint

  2023-03-31

• Supplementary Data from Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in <i>CCNE1</i>-Amplified Ovarian CancerPreprint

  2023-03-31

• Supplementary Figures S1-S9 from Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in <i>CCNE1</i>-Amplified Ovarian CancerPreprint

  2023-03-31

• Supplementary Tables S1-5 from Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in <i>CCNE1</i>-Amplified Ovarian Cancer

  2023-03-31